Novartis says buoyed by new treatments in second quarter / Photo: GABRIEL MONNET - AFP
-
Denmark hails 'binding' Greenland deal with Trump
-
Indians living in Japan on stand-by to house Asian Games athletes
-
We don't want Games host Japan losing money, says Asian Olympic official
-
Trump signs bill authorizing sweeping Russia sanctions
-
Ed Sheeran returns to stage after Palestinian controversy
-
Protesters form human chain at Kennedy Center after Trump threat
-
Asian Games to open in Japan after troubled build-up
-
Death toll from attack at police HQ in Pakistan rises to 31
-
Drone owners rush to offload devices ahead of Beijing ban
-
Trump says Denmark to give US 'permanent control' over Greenland security
-
Trump's beef policies irk Texas ranchers, testing their loyalty
-
Kennedy Center: future unclear for iconic Washington arts hub
-
Nvidia, OpenAI CEOs to attend Xi dinner at White House
-
Trump claims 'infinite' Greenland security deal with Denmark
-
Anthropic picks Accenture for in-house AI safety evaluation
-
Helicopters battle wildfire threatening Ecuador's capital
-
Balogun returns as Monaco beat Lens to continue strong Ligue 1 start
-
Brentford batter Chelsea to undo Alonso's promising start
-
'Pause' on overt repression in Venezuela, but reforms still needed: HRW
-
Kane hits Bundesliga century as Bayern rout Union
-
Global stocks mixed as yen falls despite Bank of Japan rate hike
-
Trump says CNN, MS NOW, Politico banned from White House
-
Cuba hit with seventh major blackout of the year
-
Hushing and hedging: US companies retreat on climate
-
Murray out with concussion so Wentz will start for Vikings
-
Springboks to face Fiji before 2027 Rugby World Cup
-
UN chief 'deeply regrets' US visa refusal to Abbas for annual meeting
-
Nigeria miners struggled to breathe in cell before 37 died: survivors
-
England quick Carse to face no charges over alleged nightclub assault
-
McIlroy on the charge at PGA Championship as Reed withdraws
-
Mancini brings nine newcomers into the first squad of his Italy comeback
-
McIlroy on the charge at PGA Championship
-
Czechs level Davis Cup tie against USA as South Korea eye Finals
-
Crisis-wracked Volkswagen warns of 10-bn-euro hit to profits
-
New France boss Zidane confirms Mbappe as captain after naming first squad
-
Costa Rica's Grynspan tops third informal poll for UN chief: diplomat
-
California governor signs order to explore AI 'kill switch'
-
Stock markets retreat after central bank rate hikes
-
Head leads run spree as Australia win Zimbabwe ODI series
-
Russia labels director of Cannes Grand Prix winner a 'foreign agent'
-
In-form Raphinha wants to finish career at Barcelona
-
Macron warns of Russian 'hybrid' threat after meeting presidential hopefuls
-
Warren Buffett steps down as Berkshire Hathaway chairman
-
UN holds third informal poll for new chief
-
Carrick confident Man Utd can 'work through' tough time
-
Kulusevski return can spark Spurs: De Zerbi
-
Mbappe ends Nike partnership to join Swiss brand On
-
Shakira to cap off world tour with Madrid 12-gig run
-
Liverpool boss Iraola puts Bournemouth love affair on hold
-
Isolated Syrian-Druze city blames Damascus for shortages
Novartis says buoyed by new treatments in second quarter
Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products.
Novartis said in a statement that sales in the period from April to June rose by three percent to $14.4 billion (12.6 billion euros), compared with the second quarter of 2025.
That was slightly higher than the $14 billion forecast by analysts polled by Swiss agency AWP.
The Basel-based group is facing the expiry of patents for a number of its drugs, including Entresto, a flagship treatment for heart failure.
In 2025, Entresto alone generated annual sales of $7.7 billion, even though its sales had already fallen sharply in the fourth quarter after its patent expired in the United States in July of that year.
Rhapsido, a treatment for chronic rashes that was approved in the US last September and then in the European Union at the end of April, has already generated $64 million in sales, Novartis said.
Net profit fell by 19 percent to $3.2 billion, hit by higher interest and tax expenses, the group explained.
Novartis confirmed its targets for 2026 and said it is still aiming for "low single-digit" sales growth for the whole year.
noo/nth/spm/yad
N.AbuHussein--SF-PST